Michael L. Jackson, PhD, MPH, focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator for the United States Influenza Vaccine Effectiveness (US Flu VE) Network. Using information from five sites across the country, including Kaiser Permanente Washington, this network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies.
In addition, Dr. Jackson is using data collected by the US Flu VE Network to build a simulation model for the spread of influenza, with a specific focus on understanding when new strains of the influenza virus can out-compete existing strains. This work, funded by the National Institutes of Health, aims to improve our ability to correctly choose which strains of the influenza virus to include in seasonal influenza vaccines. He also uses simulation models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenzae type b (Hib) and Neisseria meningitidis.
Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.
While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with KPWHRI from 2002 to 2007, and then a postdoctoral fellow at KPWHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to KPWHRI as an assistant investigator in 2010. He is an affiliate associate professor at the University of Washington School of Public Health.
Rogers JH, Link AC, McCulloch D, Brandstetter E, Newman KL, Jackson ML, Hughes JP, Englund JA, Boeckh M, Sugg N, Ilcisin M, Sibley TR, Fay K, Lee J, Han P, Truong M, Richardson M, Nickerson DA, Starita LM, Bedford T, Chu HY. Characteristics of COVID-19 in homeless shelters: a community-based surveillance study. Ann Intern Med. 2021 Jan;174(1):42-49. doi: 10.7326/M20-3799. Epub 2020 Sep 15. PubMed
Balasubramani GK, Choi WS, Nowalk MP, Zimmerman RK, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Jackson ML, Jackson LA, Chung JR, Spencer S, Fry AM, Patel M, Flannery B; US Flu VE Network Investigators. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19. Vaccine. 2020 Aug 12:S0264-410X(20)31032-X. doi: 10.1016/j.vaccine.2020.08.011. Online ahead of print. PubMed
Flannery B, Meece JK, Williams JV, Martin ET, Gaglani M, Jackson ML, Talbot HK. Systematic testing for influenza and COVID-19 among patients with respiratory illness. Clin Infect Dis. 2020 Jul 20:ciaa1023. doi: 10.1093/cid/ciaa1023. [Epub ahead of print]. PubMed
Jackson ML, Scott E, Kuypers J, Nalla AK, Roychoudury P, Chu HY. Epidemiology of respiratory syncytial virus across five influenza seasons among adults and children one year of age and older - Washington State, 2011/12 - 2015/16. J Infect Dis. 2021 Jan 4;223(1):147-156. doi: 10.1093/infdis/jiaa331. PubMed
Kim SS, Flannery B, Foppa IM, Chung JR, Nowalk MP, Zimmerman RK, Gaglani M, Monto AS, Martin ET, Belongia EA, McLean HQ, Jackson ML, Jackson LA, Patel M. Effects of prior season vaccination on current season vaccine effectiveness in the US Flu VE Network, 2012-13 through 2017-18. Clin Infect Dis. 2020 Jun 7:ciaa706. doi: 10.1093/cid/ciaa706. [Epub ahead of print]. PubMed
Chubak J, Anderson ML, Cook AJ, Murphy CC, Jackson ML, Green BB. Methodological considerations in calculating and analyzing proportion of time covered as a measure of longitudinal cancer screening adherence. Cancer Epidemiol Biomarkers Prev. 2020 May 28:cebp.0388.2020. doi: 10.1158/1055-9965.EPI-20-0388. [Epub ahead of print]. PubMed
Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, Jentz C, Northrup GR, Mahmud A, Reingold AL, Petersen M, Jewell NP, Young S, Bellows J. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. BMJ. 2020 May 22;369:m1923. doi: 10.1136/bmj.m1923. PubMed
Weinmann S, Irving SA, Koppolu P, Naleway AL, Belongia EA, Hambidge SJ, Jackson ML, Klein NP, Lewin B, Liles E, Marin M, Smith N, Weintraub E, Chun C. Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine. Vaccine. 2020 May 19. pii: S0264-410X(20)30612-5. doi: 10.1016/j.vaccine.2020.05.006. [Epub ahead of print]. PubMed
Chung JR, Flannery B, Gaglani M, Smith ME, Reis EC, Hickey RW, Jackson ML, Jackson LA, Belongia EA, McLean HQ, Martin ET, Segaloff HE, Kim SS, Patel MM. Patterns of influenza vaccination and vaccine effectiveness among young US children who receive outpatient care for acute respiratory tract illness. JAMA Pediatr. 2020 May 4:e200372. doi: 10.1001/jamapediatrics.2020.0372. [Epub ahead of print]. PubMed
Somayaji R, Neradilek MB, Szpiro AA, Lofy KH, Jackson ML, Goss CH, Duchin JS, Neuzil KM, Ortiz JR. Effects of air pollution and other environmental exposures on estimates of severe influenza illness, Washington, USA. Emerg Infect Dis. 2020;26(5):920-9. doi: 10.3201/eid2605.190599. PubMed
Vaccines given in last 20 years could prevent 50 million deaths in 112 countries
Answers to 4 questions about COVID-19 and this season's flu, from KPWHRI's Michael Jackson, PhD, MPH.
In a JAMA Viewpoint, Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.
Verywell Health, Jan. 13, 2021
KPWHRI’s Michael L. Jackson, PhD, MPH, talks about influenza vaccine research in the age of the pandemic.
WebMD, Sept. 2, 2020